Long-Term Cost Effectiveness of Interferon-beta-1a in the Treatment of Relapsing-Remitting Multiple Sclerosis : An Econometric Model.

Objective: To evaluate the cost effectiveness of subcutaneous interferon-beta-1a (IFNbeta-1a) 44mug three times weekly in relapsing-remitting multiple sclerosis (RRMS) using an econometric model.

Methods: Data on RRMS patients treated with IFNbeta-1a 22 or 44mug subcutaneously three times weekly or placebo for up to 4 years were obtained from the Prevention of Relapses and disability by Interferon-beta-1a Subcutaneously in Multiple Sclerosis (PRISMS) study. The area under the Expanded Disability Status Scale (EDSS) score-time curve was used as a measure of disability and the effectiveness of therapy was expressed as EDSS-months of disability prevented.

Estimating the long-term visual field consequences of average daily intraocular pressure and variance : a clinical trial comparing timolol, latanoprost and travoprost.

Objective: To estimate the long-term consequences of average daily intraocular pressure (IOP) and variance in patients treated with travoprost, latanoprost or timolol.

Design And Setting: IOP measures were derived from a 12-month randomised, double-masked, double-dummy, phase III clinical trial conducted in patients with primary open angle glaucoma (POAG) or ocular hypertension. IOP was measured at weeks 2, 12, 24 and 48, at 8am, 10am and 4pm.

Cost of illness and disease severity in a cohort of French patients with Parkinson's disease.

Objective: To assess the relationship between severity and progression of illness in Parkinson's disease and the use of healthcare resources.

Design And Setting: This was a prospective cost-of-illness study conducted in France based on clinical observation over a 6-month period of patients with Parkinson's disease treated in the hospital or community setting. Regression analyses were performed to construct the model that offered the best explanation for health expenditures using clinical and sociodemographic indicators.

The economics of TRACE. A cost-effectiveness analysis of trandolapril in postinfarction patients with left ventricular dysfunction.

Objective: The objective of the study was to compute a cost-effectiveness ratio relating the economic cost of trandolapril to the number of effectiveness units (i.e. life-years) gained.